文献速递冠心病血脂与心血管预防

RESPECT-EPA随机试验:他汀联合二十碳五烯酸乙酯用于冠心病二级预防

Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA).
PubMed 文献 · Circulation · 2024-06-14

RESPECT-EPA是一项前瞻性、多中心、随机、开放标签、盲终点研究,纳入3884例稳定性冠心病患者,其中2506例EPA/AA比值低(<0.4)者随机接受二十碳五烯酸乙酯每日1800mg或对照。中位随访5年,主要复合终点发生率两组分别为9.1%和12.6%(HR 0.79,95%CI 0.62-1.00,P=0.055),未达统计学显著;冠状动脉事件次要复合终点显著降低(HR 0.73,95%CI 0.55-0.97)。

要点

  • 低EPA/AA比值(<0.4)的稳定性冠心病患者中,EPA组主要复合终点风险数值上降低但未达统计学显著。
  • EPA组冠状动脉事件次要复合终点显著低于对照组(HR 0.73,95%CI 0.55-0.97)。
  • EPA组新发心房颤动发生率显著高于对照组(3.1% vs 1.6%,P=0.017)。

核心结论

  • 在稳定性冠心病、EPA/AA比值低且接受他汀治疗的患者中,二十碳五烯酸乙酯治疗使心血管事件风险数值上降低但未达统计学显著。

研究设计与样本

  • 前瞻性、多中心、随机、开放标签、盲终点研究,在日本95个中心纳入3884例稳定性冠心病患者,其中2506例低EPA/AA比值(<0.4)者随机分为EPA组(1249例)和对照组(1257例)。

主要发现

  • 中位随访5年,主要复合终点在EPA组1225例中发生112例(9.1%),对照组1235例中发生155例(12.6%),HR 0.79(95%CI 0.62-1.00),P=0.055。
  • 冠状动脉事件次要复合终点EPA组81/1225例(6.6%),对照组120/1235例(9.7%),HR 0.73(95%CI 0.55-0.97)。
  • 不良事件两组无差异,但新发心房颤动发生率EPA组显著更高(3.1% vs 1.6%,P=0.017)。

关键数值与推荐

  • 入组患者EPA/AA比值<0.4,EPA组每日服用二十碳五烯酸乙酯1800mg。
  • 主要复合终点包括心血管死亡、非致死性心肌梗死、非致死性缺血性卒中、不稳定型心绞痛和冠状动脉血运重建。

临床怎么用

  • 对于接受他汀治疗且EPA/AA比值低的稳定性冠心病患者,可考虑加用二十碳五烯酸乙酯以降低冠状动脉事件风险,但需权衡新发心房颤动风险。

局限性

  • 研究为开放标签设计,主要终点未达统计学显著,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low plasma levels of eicosapentaenoic acid (EPA) are associated with cardiovascular events. This trial aimed to assess the clinical benefits of icosapent ethyl in patients with coronary artery disease, a low EPA/arachidonic acid (AA) ratio, and statin treatment. METHODS: In this prospective, multicenter, randomized, open-label, blinded end-point study, patients with stable coronary artery disease and a low EPA/AA ratio (<0.4) were randomized to EPA (1800 of icosapent ethyl administered daily) or control group. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, unstable angina pectoris, and coronary revascularization. The secondary composite end points of coronary events included sudden cardiac death, fatal and nonfatal myocardial infarction, unstable angina requiring emergency hospitalization and coronary revascularization, or coronary revascularization. RESULTS: Overall, 3884 patients were enrolled at 95 sites in Japan. Among them, 2506 patients had a low EPA/AA ratio, and 1249 and 1257 patients were randomized to the EPA and control group, respectively. The median EPA/AA ratio was 0.243 (interquartile range, 0.180-0.314) and 0.235 (interquartile range, 0.163-0.310) in the EPA and control group, respectively. Over a median period of 5 years, the primary end point occurred in 112 of 1225 patients (9.1%) and 155 of 1235 patients (12.6%) in the EPA and control group, respectively (hazard ratio, 0.79 [95% CI, 0.62-1.00]; P=0.055). Meanwhile, the secondary composite end point of coronary events in the EPA group was significantly lower (81/1225 [6.6%] versus 120/1235 [9.7%] patients; hazard ratio, 0.73 [95% CI, 0.55-0.97]). Adverse events did not differ between the groups, but the rate of new-onset atrial fibrillation was significantly higher in the EPA group (3.1% versus 1.6%; P=0.017). CONCLUSIONS: Icosapent ethyl treatment resulted in a numerically lower risk of cardiovascular events that did not reach statistical significance in patients with chronic coronary artery disease, a low EPA/AA ratio, and statin treatment. REGISTRATION: URL: https://www.umin.ac.jp/ctr/; Unique identifier: UMIN000012069.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Miyauchi K, Iwata H, Nishizaki Y, et al. Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy-Statin and Eicosapentaenoic Acid (RESPECT-EPA). Circulation. 2024. PMID: 38873793. doi:10.1161/CIRCULATIONAHA.123.065520

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。